News

Owens & Minor will pay $30.2 million for the net assets of The Burrows Company and will assume the company’s debt. The final purchase price will be subject

The new biomarker, present in many common cancers, is a target of drugs being evaluated by Lixte and the National Institute of Neurological Disorders and Stroke (NINDS) for

According to the company, the small cationic peptides covered by the University of Michigan intellectual property are capable of forming stable siRNA nanoparticle complexes, thereby protecting the siRNA

The study is designed to evaluate the safety and efficacy of a novel non-dopaminergic approach for reestablishing motor function in Parkinson’s patients who are sub-optimally responsive to drug

The Karolinska Institute has completed a 38-subject Phase I trial testing a prime-boost HIV vaccine regimen using three doses of unadjuvanted DNA vaccines over a three-month period followed

Protect AF evaluated the Watchman left atrial appendage (LAA) closure technology versus the current standard of care, warfarin, in patients with non-valvular atrial fibrillation at risk of stroke.

MASP-2, or mannan-binding lectin-associated serine protease-2, mediates activation of the complement system via the lectin pathway and is linked to multiple potential indications across a wide range of

Under the partnership, Medco and the FDA will jointly develop research projects, programs and strategies in the area of pharmacogenomics, collectively aimed at improving patient health and quality

Intended for use by donor centers, reference laboratories and hospitals for blood group serology testing, these traditional blood bank reagents complement Biotest’s existing portfolio of automated reagents that